Stratos Wealth Partners LTD. Purchases 3,178 Shares of GlaxoSmithKline plc (GSK)

Share on StockTwits

Stratos Wealth Partners LTD. raised its position in GlaxoSmithKline plc (NYSE:GSK) by 21.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,010 shares of the pharmaceutical company’s stock after purchasing an additional 3,178 shares during the period. Stratos Wealth Partners LTD.’s holdings in GlaxoSmithKline were worth $753,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. D Orazio & Associates Inc. lifted its holdings in shares of GlaxoSmithKline by 200.0% during the 1st quarter. D Orazio & Associates Inc. now owns 600 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 400 shares during the period. Claybrook Capital LLC purchased a new position in shares of GlaxoSmithKline during the 4th quarter worth about $26,000. Berman Capital Advisors LLC purchased a new position in shares of GlaxoSmithKline during the 4th quarter worth about $32,000. Orrstown Financial Services Inc. lifted its holdings in shares of GlaxoSmithKline by 210.7% during the 1st quarter. Orrstown Financial Services Inc. now owns 932 shares of the pharmaceutical company’s stock worth $39,000 after acquiring an additional 632 shares during the period. Finally, Riverview Trust Co purchased a new position in shares of GlaxoSmithKline during the 1st quarter worth about $39,000. Institutional investors own 11.12% of the company’s stock.

GSK traded up $0.03 on Tuesday, reaching $39.39. 51,193 shares of the company’s stock were exchanged, compared to its average volume of 2,754,994. The company has a market cap of $97.77 billion, a PE ratio of 12.47, a price-to-earnings-growth ratio of 2.04 and a beta of 0.74. GlaxoSmithKline plc has a twelve month low of $36.41 and a twelve month high of $42.36. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.13. The firm had revenue of $9.98 billion during the quarter, compared to the consensus estimate of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 171.27%. On average, sell-side analysts predict that GlaxoSmithKline plc will post 2.92 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be given a dividend of $0.4953 per share. This represents a $1.98 dividend on an annualized basis and a yield of 5.03%. The ex-dividend date of this dividend is Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 61.71%.

In other GlaxoSmithKline news, Director Plc Glaxosmithkline bought 325,000 shares of the company’s stock in a transaction that occurred on Monday, April 22nd. The stock was purchased at an average price of $18.00 per share, with a total value of $5,850,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by corporate insiders.

Several brokerages have recently weighed in on GSK. UBS Group lowered shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd. Zacks Investment Research upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a report on Tuesday, April 23rd. Finally, Shore Capital lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $41.83.

WARNING: This article was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://weekherald.com/2019/05/21/stratos-wealth-partners-ltd-purchases-3178-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: What are the components of an earnings report?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.